Kai En Chan

3.3k total citations · 2 hit papers
46 papers, 1.1k citations indexed

About

Kai En Chan is a scholar working on Epidemiology, Endocrinology, Diabetes and Metabolism and Hepatology. According to data from OpenAlex, Kai En Chan has authored 46 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Epidemiology, 14 papers in Endocrinology, Diabetes and Metabolism and 12 papers in Hepatology. Recurrent topics in Kai En Chan's work include Liver Disease Diagnosis and Treatment (29 papers), Diet, Metabolism, and Disease (12 papers) and Liver Disease and Transplantation (9 papers). Kai En Chan is often cited by papers focused on Liver Disease Diagnosis and Treatment (29 papers), Diet, Metabolism, and Disease (12 papers) and Liver Disease and Transplantation (9 papers). Kai En Chan collaborates with scholars based in Singapore, United States and United Kingdom. Kai En Chan's co-authors include Mark Muthiah, Cheng Han Ng, Wen Hui Lim, Daniel Q. Huang, Eunice Xiang Xuan Tan, Margaret LP Teng, Ju Dong Yang, Nicholas Chew, Darren Jun Hao Tan and Mazen Noureddin and has published in prestigious journals such as PLoS ONE, Hepatology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Kai En Chan

43 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Global incidence and prevalence of nonalcoholic fatty liver disease

2022 351 citations Cheng Han Ng, Daniel Q. Huang et al. Clinical and Molecular Hepatology profile →
Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals

2022 184 citations Kai En Chan, Ansel Shao Pin Tang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kai En Chan Singapore	16	843	422	343	156	150	46	1.1k
Jian-Gao Fan China	4	915 1.1×	383 0.9×	324 0.9×	169 1.1×	126 0.8×	5	1.2k
Jie Ning Yong Singapore	18	780 0.9×	316 0.7×	408 1.2×	92 0.6×	81 0.5×	38	1.1k
Shireene Ratna Vethakkan Malaysia	17	655 0.8×	557 1.3×	209 0.6×	177 1.1×	189 1.3×	60	1.2k
Rochelle Collantes United States	13	938 1.1×	332 0.8×	378 1.1×	122 0.8×	195 1.3×	19	1.1k
Nancy Solı́s Chile	22	640 0.8×	325 0.8×	262 0.8×	273 1.8×	165 1.1×	53	1.3k
Sherry Boyett United States	12	959 1.1×	244 0.6×	512 1.5×	295 1.9×	164 1.1×	19	1.2k
Ansel Shao Pin Tang Singapore	13	610 0.7×	235 0.6×	310 0.9×	70 0.4×	67 0.4×	31	782
Dante Romagnoli Italy	14	1.6k 1.9×	820 1.9×	616 1.8×	214 1.4×	199 1.3×	25	1.8k
Yasushi Ide Japan	8	447 0.5×	275 0.7×	168 0.5×	103 0.7×	223 1.5×	19	700
Kent R. Wehmeier United States	12	508 0.6×	346 0.8×	126 0.4×	214 1.4×	127 0.8×	16	901

Countries citing papers authored by Kai En Chan

Since Specialization

Citations

This map shows the geographic impact of Kai En Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kai En Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kai En Chan more than expected).

Fields of papers citing papers by Kai En Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kai En Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kai En Chan. The network helps show where Kai En Chan may publish in the future.

Co-authorship network of co-authors of Kai En Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Kai En Chan. A scholar is included among the top collaborators of Kai En Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kai En Chan. Kai En Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chan, Kai En, et al.. (2025). Effects of music therapy on intravitreal injections: a randomised clinical trial. Singapore Medical Journal.

Ng, Qin Xiang, et al.. (2024). Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: a scoping review. Health Economics Review. 14(1). 42–42. 12 indexed citations

Quek, Jingxuan, Darren Jun Hao Tan, Kai En Chan, et al.. (2023). Quality Assessment of Ultrasound and Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance: A Systematic Review and Meta-Analysis. Digestive Diseases. 41(5). 757–766. 6 indexed citations

Lim, Wen Hui, Caitlyn Tan, Jieling Xiao, et al.. (2023). De novo metabolic syndrome after liver transplantation: a meta-analysis on cumulative incidence, risk factors, and outcomes. Liver Transplantation. 29(4). 413–421. 7 indexed citations

Kong, Gwyneth, Yip Han Chin, Kannan Shankar, et al.. (2023). A two‐decade population‐based study on the effect of hypertension in the general population with obesity in the United States. Obesity. 31(3). 832–840. 13 indexed citations

Zeng, Rebecca Wenling, Jie Ning Yong, Darren Jun Hao Tan, et al.. (2023). Meta‐analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. Alimentary Pharmacology & Therapeutics. 57(6). 600–609. 52 indexed citations

Huang, Daniel Q., Kai En Chan, Caitlyn Tan, et al.. (2023). Meta‐analysis: Prevalence of significant or advanced fibrosis in adults with alpha‐1‐antitrypsin deficiency. Alimentary Pharmacology & Therapeutics. 58(2). 152–158. 3 indexed citations

Chee, Douglas, Cheng Han Ng, Kai En Chan, et al.. (2023). The Past, Present, and Future of Noninvasive Test in Chronic Liver Diseases. Medical Clinics of North America. 107(3). 397–421. 2 indexed citations

Tan, Bryan C., Han Shi Jocelyn Chew, Rachel Sze Jen Goh, et al.. (2023). Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. International Journal of Obesity. 47(8). 677–685. 49 indexed citations

10.

Yaow, Clyve Yu Leon, Bryan Chong, Yip Han Chin, et al.. (2023). Higher risk of adverse cardiovascular outcomes in females with type 2 diabetes Mellitus: an Umbrella review of systematic reviews. European Journal of Preventive Cardiology. 30(12). 1227–1235. 15 indexed citations

11.

Lin, Chaoxing, Yip Han Chin, Bryan Chong, et al.. (2023). Mortality, Cardiovascular, and Medication Outcomes in Patients With Myocardial Infarction and Underweight in a Meta-Analysis of 6.3 Million Patients. The American Journal of Cardiology. 196. 1–10. 11 indexed citations

12.

Chin, Yip Han, Chaoxing Lin, Gwyneth Kong, et al.. (2022). Meta-analysis of the Placebo and Nocebo effects associated with Placebo treatment in randomized trials of lipid-lowering therapies. European Heart Journal - Quality of Care and Clinical Outcomes. 9(5). 511–519. 16 indexed citations

13.

Li, Wenhao, Cheng Han Ng, Jingxuan Quek, et al.. (2022). The growing prevalence of nonalcoholic fatty liver disease (NAFLD), determined by fatty liver index, amongst young adults in the United States. A 20-year experience. The HKU Scholars Hub (University of Hong Kong). 2(4). 19–19. 5 indexed citations

14.

Xiao, Jieling, Cheng Han Ng, Yip Han Chin, et al.. (2022). A Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia. Journal of Clinical and Translational Hepatology. 0(0). 0–0. 4 indexed citations

15.

Ng, Cheng Han, Kai En Chan, Mazen Noureddin, et al.. (2022). IDDF2022-ABS-0134 Hypertension is prevalent in non-alcoholic fatty liver disease (nafld) and increases all cause and cardiovascular mortality. A82.2–A83.

16.

Lim, Grace En Hui, Ansel Shao Pin Tang, Yip Han Chin, et al.. (2022). A network meta-analysis of 12,116 individuals from randomized controlled trials in the treatment of depression after acute coronary syndrome. PLoS ONE. 17(11). e0278326–e0278326. 5 indexed citations

17.

Muthiah, Mark, Cheng Han Ng, Kai En Chan, et al.. (2022). Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis. Annals of Hepatology. 28(1). 100762–100762. 26 indexed citations

18.

Ng, Cheng Han, Kai En Chan, Yip Han Chin, et al.. (2022). The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease. Clinical and Molecular Hepatology. 28(3). 565–574. 55 indexed citations

19.

Lim, Wen Hui, Kai En Chan, Cheng Han Ng, et al.. (2022). A qualitative systematic review of anonymous/unspecified living kidney and liver donors’ perspectives. PLoS ONE. 17(12). e0277792–e0277792. 5 indexed citations

20.

Fu, Clarissa Elysia, Cheng Han Ng, Nicholas Chew, et al.. (2022). A poor perspective of self weight significantly increases adverse outcomes in non-alcoholic fatty liver disease (NAFLD). Frontiers in Medicine. 9. 977552–977552. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact